Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation
Open Access
- 3 October 2011
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 19 (23), 7168-7180
- https://doi.org/10.1016/j.bmc.2011.09.056
Abstract
No abstract availableKeywords
Funding Information
- Austrian Science Fund (S10702/10711, S10703, S10709/10713)
This publication has 50 references indexed in Scilit:
- Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidumBioorganic & Medicinal Chemistry, 2011
- Human hydroxysteroid dehydrogenases and pre-receptor regulation: Insights into inhibitor design and evaluationThe Journal of Steroid Biochemistry and Molecular Biology, 2011
- Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME propertiesBioorganic & Medicinal Chemistry Letters, 2010
- Computer-Aided Discovery, Validation, and Mechanistic Characterization of Novel Neolignan Activators of Peroxisome Proliferator-Activated Receptor γMolecular Pharmacology, 2010
- Inhibition of 11β–hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humansJCI Insight, 2009
- Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activationProceedings of the National Academy of Sciences, 2008
- DrugBank: a knowledgebase for drugs, drug actions and drug targetsNucleic Acids Research, 2007
- FXR, a multipurpose nuclear receptorTrends in Biochemical Sciences, 2006
- Announcing the worldwide Protein Data BankNature Structural & Molecular Biology, 2003
- Improved protein–ligand docking using GOLDProteins-Structure Function and Bioinformatics, 2003